IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

(in CHF 1 000)

 

 

Notes

 

01.01.–31.03.2021

 

01.01.–31.03.2020

Operating income

 

 

 

 

 

 

Net gains from securities

 

4

 

235 555

 

Dividend income

 

 

 

 

243

Foreign exchange gains

 

 

 

207

 

38

Other income

 

 

 

3

 

3

 

 

 

 

235 765

 

284

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

Net losses from securities

 

4

 

 

(746 726)

Finance expenses

 

 

 

(43)

 

(225)

Administrative expenses

 

7

 

(13 078)

 

(9 685)

Other expenses

 

 

 

(1 677)

 

(1 585)

 

 

 

 

(14 798)

 

(758 221)

Profit/(loss) before tax

 

8

 

220 967

 

(757 937)

 

 

 

 

 

 

 

Income taxes

 

 

 

(19)

 

(17)

Profit/(loss) for the period

 

 

 

220 948

 

(757 954)

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

220 948

 

(757 954)

 

 

 

 

 

 

 

Earnings/(loss) per share in CHF

 

 

 

3.99

 

(13.68)

Diluted earnings/(loss) per share in CHF

 

 

 

3.99

 

(13.68)

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer